scholarly journals Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic

2020 ◽  
Author(s):  
Richard M. Bergenstal ◽  
Jennifer E. Layne ◽  
Howard Zisser ◽  
Robert A. Gabbay ◽  
Nathan A. Barleen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real Time ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Diabetes Clinic

scholarly journals Resistance to Acetaminophen Interference in a Novel Continuous Glucose Monitoring System

2018 ◽  
Vol 12 (2) ◽  
pp. 393-396 ◽  
Author(s):  
Peter Calhoun ◽  
Terri Kang Johnson ◽  
Jonathan Hughes ◽  
David Price ◽  
Andrew K. Balo
Keyword(s):  
Type 2 Diabetes ◽  
Real Time ◽  
Monitoring System ◽  
Continuous Glucose Monitoring ◽  
Interference Effect ◽  
Glucose Monitoring ◽  
Post Dose ◽  
The Difference

Acetaminophen (APAP) can cause erroneously high readings in real-time continuous glucose monitoring (rtCGM) systems. APAP-associated bias in an investigational rtCGM system (G6) was evaluated by taking the difference in glucose measurements between rtCGM and YSI from 1 hour before to 6 hours after a 1-g oral APAP dose in 66 subjects with type 1 or type 2 diabetes. The interference effect was defined as the average post-dose (30-90 minutes) bias minus the average baseline bias for each subject. The clinically meaningful interference effect was defined as 10 mg/dL. The G6 system’s overall mean (±SD) interference effect was 3.1 ± 4.8 mg/dL (one-sided upper 95% CI = 4.1 mg/dL), significantly lower than 10 mg/dL. The G6 system’s resistance to APAP interference should provide reassurance to those using the drug.

scholarly journals The Effect of Discontinuing Continuous Glucose Monitoring in Adults with Type 2 Diabetes Treated with Basal Insulin

2021 ◽  
Author(s):  
Grazia Aleppo ◽  
Roy W. Beck ◽  
Ryan Bailey ◽  
Katrina J. Ruedy ◽  
Peter Calhoun ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real Time ◽  
Continuous Glucose Monitoring ◽  
Basal Insulin ◽  
Glucose Monitoring ◽  
Blood Glucose Monitoring ◽  
Time In Range ◽  
Bolus Insulin ◽  
Design And Methods

<b>Objective: </b>To explore the effect of discontinuing continuous glucose monitoring (CGM) after 8 months of CGM use in adults with type 2 diabetes treated with basal without bolus insulin. <p><b>Research Design and Methods:</b> Multi-center trial with an initial randomization to either real-time CGM or blood glucose monitoring (BGM) for 8 months, followed by 6 months in which the BGM Group continued to use BGM (N=57) and the CGM Group was re-randomized either to continue CGM (N=53) or discontinue CGM with resumption of BGM for glucose monitoring (N=53). </p> <p><b>Results: </b>In the group that discontinued CGM, mean time in range 70-180 mg/dL (TIR), which improved from 38% prior to initiating CGM to 62% after 8 months of CGM, decreased after discontinuing CGM to 50% at 14 months (mean change from 8 to 14 months = -12%, 95% CI -21% to -3%, P=0.01). In the group continuing CGM, there was little change in TIR from 8 to 14 months (baseline 44%, 8 months 56%, 14 months 57%; mean change 8 to 14 months = 1%, 95% CI -11% to 12%, P=0.89). Comparing the two groups at 14 months, the adjusted treatment group difference in mean TIR was -6% (95% CI -16% to 4%, P=0.20).</p> <p><b>Conclusions: </b>In adults with type 2 diabetes treated with basal insulin who had been using real-time CGM for 8 months, discontinuing CGM resulted in a loss of about half of the initial gain in TIR that had been achieved during CGM use.</p>

scholarly journals Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

10.2196/21778 ◽  
2020 ◽  
Vol 22 (8) ◽  
pp. e21778 ◽  
Author(s):  
Amit R Majithia ◽  
Coco M Kusiak ◽  
Amy Armento Lee ◽  
Francis R Colangelo ◽  
Robert J Romanelli ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Prospective Trial ◽  
Glucose Monitoring ◽  
Mobile App ◽  
Diabetes Clinic ◽  
Percent Time ◽  
Glycemic Outcomes

Background The Onduo virtual diabetes clinic (VDC) for people with type 2 diabetes (T2D) combines a mobile app, remote personalized lifestyle coaching, connected devices, and live video consultations with board-certified endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices for intermittent use. Objective This prospective single-arm study evaluated glycemic outcomes associated with participation in the Onduo VDC for 4 months. Methods Adults aged ≥18 years with T2D and a baseline glycated hemoglobin (HbA1c) of ≥8% to ≤12% were enrolled from 2 primary care centers from February 2019 to October 2019. Participants were asked to engage at ≥1 time per week with their care team and to participate in a telemedicine consultation with a clinic endocrinologist for diabetes medication review. Participants were asked to use a RT-CGM device and wear six 10-day sensors (total 60 days of sensor wear) intermittently over the course of 4 months. The primary outcome was change in HbA1c at 4 months from baseline. Other endpoints included change in weight and in RT-CGM glycemic metrics, including percent time <70, 70-180, 181-250, and >250 mg/dL. Changes in blood pressure and serum lipids at 4 months were also evaluated. Results Participants (n=55) were 57.3 (SD 11.6) years of age, body mass index 33.7 (SD 7.2), and 40% (22/55) female. HbA1c decreased significantly by 1.6% (SD 1%; P<.001). When stratified by baseline HbA1c of 8.0% to 9.0% (n=36) and >9.0% (n=19), HbA1c decreased by 1.2% (SD 0.6%; P<.001) and 2.4% (SD 1.3%; P<.001), respectively. Continuous glucose monitoring–measured (n=43) percent time in range (TIR) 70-180 mg/dL increased by 10.2% (SD 20.5%; P=.002), from 65.4% (SD 23.2%) to 75.5% (SD 22.7%), which was equivalent to a mean increase of 2.4 hours TIR per day. Percent time 181-250 mg/dL and >250 mg/dL decreased by 7.2% (SD 15.4; P=.005) and 3.0% (SD 9.4; P=.01), respectively. There was no change in percent time <70 mg/dL. Mean weight decreased by 9.0 lb (SD 10.4; P<.001). Significant improvements were also observed in systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, and triglycerides (P=.04 to P=<.001). Conclusions Participants in the Onduo VDC experienced significant improvement in HbA1c, increased TIR, decreased time in hyperglycemia, and no increase in hypoglycemia at 4 months. Improvements in other metabolic health parameters including weight and blood pressure were also observed. In conclusion, the Onduo VDC has potential to support people with T2D and their clinicians between office visits by increasing access to specialty care and advanced diabetes technology including RT-CGM. Trial Registration ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381

Equivalent Efficacy of Intensive Self-Monitoring of Blood Glucose to Real-Time Continuous Glucose Monitoring in Adults with Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 913-P
Author(s):  
YUYA TAKANO ◽  
YULIA NAMIKI ◽  
HIROKO HIIRAGI ◽  
TAKU YAMADA ◽  
HIROTO SASAKI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Real Time ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Self Monitoring ◽  
Equivalent Efficacy

scholarly journals Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study

2019 ◽  
Vol 10 (2) ◽  
pp. 509-522 ◽  
Author(s):  
Penelope J. Taylor ◽  
Campbell H. Thompson ◽  
Natalie D. Luscombe-Marsh ◽  
Thomas P. Wycherley ◽  
Gary Wittert ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Pilot Study ◽  
Real Time ◽  
Lifestyle Intervention ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring

scholarly journals Heterogeneity of Responses to Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 2 Diabetes and Its Implications for Application

Diabetes Care ◽  
2012 ◽  
Vol 36 (4) ◽  
pp. 786-792 ◽  
Author(s):  
S. J. Fonda ◽  
S. J. Salkind ◽  
M. S. Walker ◽  
M. Chellappa ◽  
N. Ehrhardt ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real Time ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring
Sign in / Sign up

Export Citation Format

Share Document